Startups
Advanced Biological Laboratories (ABL), S.A., is a diagnostic and medical software company founded in 2000 as a spin-off from CRP-Santé (https://www.lih.lu/) Luxembourg.
ABL's products offer to infectious disease clinicians, virology and microbiology laboratories
- Assays and standalone software systems for accredited laboratories (i.e. ISO 15189), mainly for microbiology applications (related to HIV, SARS-CoV-2, Tuberculosis, HCV, HBV, HPV, CMV, HPV, Flu, 16s RNA…) for clinical genotyping through sequencing (DeepChek®), DNA and RNA detection and quantification (UltraGene®), including powerful downstream analysis software applications fully integrated with knowledge databases and analysis systems for capillary and high-throughput Next Generation Sequencing data.
- Clinical software applications for infectious diseases units
- IT dashboards and clinical database aggregation applications for research and clinical management
ABL took in 2013 the rights to all viral hepatitis B & C related assets from EVIVAR MEDICAL as well as a personalized medicine electronic medical record system (EMR) in infectious disease from GlaxoSmithKline in 2016. In July 2018, acquired CDL Pharma to develop CRO related services and assays manufacturing capacity. In June 2019, ABL created its affiliate in the USA (AdvancedDx Biological Laboratories) covering the entire North American territory.
ABL has a comprehensive suite of healthcare management products, including Nadis®, TherapyEdge®, ViroScore®, SeqHepB, DeepChek®, UltraGene®, VisibleChek®, HepatiC®, BacterioChek, MicrobioChek and the DPM used for data and patient management, monitoring and personalized reporting applications. Since 2012, some of ABL's products are CE-IVD marked. In 2020, ABL got CE-IVD marking for its DeepChek®-HIV assays as well as for its UltraGene Combo2ScreenSARS-CoV-2 assay.
For more information, visit www.ablsa.com.
ABL's products offer to infectious disease clinicians, virology and microbiology laboratories
- Assays and standalone software systems for accredited laboratories (i.e. ISO 15189), mainly for microbiology applications (related to HIV, SARS-CoV-2, Tuberculosis, HCV, HBV, HPV, CMV, HPV, Flu, 16s RNA…) for clinical genotyping through sequencing (DeepChek®), DNA and RNA detection and quantification (UltraGene®), including powerful downstream analysis software applications fully integrated with knowledge databases and analysis systems for capillary and high-throughput Next Generation Sequencing data.
- Clinical software applications for infectious diseases units
- IT dashboards and clinical database aggregation applications for research and clinical management
ABL took in 2013 the rights to all viral hepatitis B & C related assets from EVIVAR MEDICAL as well as a personalized medicine electronic medical record system (EMR) in infectious disease from GlaxoSmithKline in 2016. In July 2018, acquired CDL Pharma to develop CRO related services and assays manufacturing capacity. In June 2019, ABL created its affiliate in the USA (AdvancedDx Biological Laboratories) covering the entire North American territory.
ABL has a comprehensive suite of healthcare management products, including Nadis®, TherapyEdge®, ViroScore®, SeqHepB, DeepChek®, UltraGene®, VisibleChek®, HepatiC®, BacterioChek, MicrobioChek and the DPM used for data and patient management, monitoring and personalized reporting applications. Since 2012, some of ABL's products are CE-IVD marked. In 2020, ABL got CE-IVD marking for its DeepChek®-HIV assays as well as for its UltraGene Combo2ScreenSARS-CoV-2 assay.
For more information, visit www.ablsa.com.
Overview
Location
Luxembourg
Employees
11-50
Founded date
2000
Investors 1
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 2
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Apr 22, 2025 | Advanced Biological Laboratories (ABL) S.A Inks Licensing Agreement with the Institut Pasteur for HPV RNA-Seq Technology | HPV Transcriptome as a Game-Changing Biomarker for Detection, Genotyping, and Monitoring of HPV-Associated Cervical High-Grade Cytology LUXEMBOURG, LUXEMBOURG, April 22, 2025 /EINPresswire.com/ -- Advanced Biological Laboratories (ABL), a d... |
Reviews 0
FAQ about ABL (Advanced Biological Laboratories)
When was ABL (Advanced Biological Laboratories) founded?
ABL (Advanced Biological Laboratories) was founded in 2000.
What has the press written about ABL (Advanced Biological Laboratories)?
Parsers VC has collected 2 articles mentioning ABL (Advanced Biological Laboratories), among them “Advanced Biological Laboratories (ABL) S.A Inks Licensing Agreement with the Institut Pasteur for HPV RNA-Seq Technology” (Apr 22, 2025).
Is ABL (Advanced Biological Laboratories) still active?
Yes, ABL (Advanced Biological Laboratories) is active; its latest activity on Parsers VC dates from Oct 22, 2025.